QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 barinthus-biotherapeutics-and-clywedog-therapeutics-enters-into-a-definitive-all-stock-merger-agreement-to-form-combined-company-before-transaction-closes-the-combined-company-may-initiate-partial-tender-offer-to-purchase-up-to-27m-worth-of-its-outstanding-shares-held-by-barinthus-bio-shareholders

Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio"), an immunology and inflammation company focused on develo...

 barinthus-biotherapeutics-q2-eps-052-misses-033-estimate

Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(0.52) per share which missed the analyst consensus estim...

 barinthus-biotherapeutics-q1-eps-049-misses-036-estimate

Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(0.49) per share which missed the analyst consensus estim...

 hc-wainwright--co-reiterates-buy-on-barinthus-biotherapeutics-maintains-3-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Barinthus Biotherapeutics (NASDAQ:BRNS) with a Buy and maintains $3 price...

 barinthus-biotherapeutics-fy-2024-gaap-eps-155-beats-167-estimate-sales-1497m-inline

Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(1.55) per share which beat the analyst consensus estimat...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION